Polyneuropathien im Alter

Melissa Held; Nurcan Üçeyler

doi:10.1055/a-2233-5854

Klinische Neurophysiologie, Table of Contents

Klinische Neurophysiologie 2024; 55(01): 33-52
DOI: 10.1055/a-2233-5854

CME-Fortbildung

Polyneuropathien im Alter

Polyneuropathies in Elderly Individuals

Melissa Held

,

Nurcan Üçeyler

Abstract

Polyneuropathien (PNP) zählen zu den häufigsten neurologischen Erkrankungen des höheren Lebensalters. Durch Beeinträchtigung der Mobilität, Erhöhung des Sturzrisikos und neuropathische Schmerzen können sie die Lebensqualität der Patienten deutlich einschränken. Aufgrund der Vielzahl an möglichen Ursachen und weil häufig mehrere potenzielle Auslöser vorliegen, ist die Diagnostik gerade in höherem Lebensalter schwierig und erfordert ein systematisches Vorgehen.

Abstract

Polyneuropathies are among the most common neurological diseases in elderly individuals. They can negatively impact patients’ health-related quality of life via impaired mobility, increased risk of falling, and neuropathic pain. Diagnosis of polyneuropathies in elderly individuals is especially challenging due to their multimodal etiology and requires a systematic approach.

Schlüsselwörter

Neuropathie - Altern - neurologische Erkrankung - kognitive Funktion

Key word

Neuropathy - aging - neurological disease - cognitive function

Full Text

References

Literatur
1 Lauria G, Merkies IS, Faber CG. Small fibre neuropathy. Curr Opin Neurol 2012; 25: 542-549
2 Hanewinckel R, van Oijen M, Ikram MA. et al. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016; 31: 5-20
3 Visser NA, Notermans NC, Linssen RS. et al. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015; 84: 259-264
4 England JD, Asbury AK. Peripheral neuropathy. Lancet 2004; 363: 2151-2161
5 Sommer C, Richter H, Rogausch JP. et al. A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol 2011; 11: 104
6 Treede RD, Jensen TS, Campbell JN. et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635
7 Heuss D, Hund E, Klehmet J et al. Diagnostik bei Polyneuropathien, S1-Leitlinie 2019. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie 2019. AWMF-Registernummer 030/067. Im Internet: https://www.awmf.org/leitlinien/detail/ll/030-067.html Stand: 02.10.2019
8 Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002; 25: 2048-2052
9 Merkies IS, Schmitz PI, van der Meche FG. et al. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiat 2002; 72: 596-601
10 Taylor PK. Non-linear effects of age on nerve conduction in adults. J Neurol Sci 1984; 66: 223-234
11 Rolke R, Magerl W, Campbell KA. et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 2006; 10: 77-88
12 Dräger B, Young P. [Pragmatic Diagnosis of Hereditary Neuropathies]. Akt Neurol 2016; 43: 256-266
13 Goedee HS, van der Pol WL, van Asseldonk JH. et al. Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology 2017; 88: 143-151
14 Lichtenstein T, Sprenger A, Weiss K. et al. MRI biomarkers of proximal nerve injury in CIDP. Ann Clin Transl Neurol 2018; 5: 19-28
15 Kronlage M, Pitarokoili K, Schwarz D. et al. Diffusion tensor imaging in chronic inflammatory demyelinating polyneuropathy: diagnostic accuracy and correlation with electrophysiology. Invest Radiol 2017; 52: 701-707
16 Mellgren SI, Lindal S. Nerve biopsy – some comments on procedures and indications. Acta Neurol Scand 2011; 124: 64-70
17 Vrancken AF, Gathier CS, Cats EA. et al. The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy. Eur J Neurol 2011; 18: 49-58
18 Üçeyler N, Devigili G, Toyka KV. et al. Skin biopsy as an additional diagnostic tool in non-systemic vasculitic neuropathy. Acta Neuropathol 2010; 120: 109-116
19 Pop-Busui R, Boulton AJ, Feldman EL. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-154
20 Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes 2018; 9: 1-24
21 Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010; 67: 534-541
22 Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2017; 2: CD001798
23 Hattori N, Misu K, Koike H. et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2001; 184: 57-63
24 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First revision. J Peripher Nerv Syst 2010; 15: 1-9
25 Sommer C, Gold R, Heuss D et al. Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden, S2e-Leitlinie, 2018. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie 2018. AWMF-Registernummer 030-130. Im Internet: https://www.awmf.org/leitlinien/detail/ll/030-130.html Stand: 02.10.2019
26 Collins MP, Dyck PJ, Gronseth GS. et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 2010; 15: 176-184
27 Rison RA, Beydoun SR. Paraproteinemic neuropathy: a practical review. BMC Neurol 2016; 16: 13
28 Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1: 294-305
29 Zajaczkowska R, Kocot-Kepska M, Leppert W. et al. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci 2019;
30 Gu Y, Menzies AM, Long GV. et al. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 2017; 45: 14-17
31 Romagnolo A, Merola A, Artusi CA. et al. Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 2019; 6: 96-103
32 Triantafyllou NI, Nikolaou C, Boufidou F. et al. Folate and vitamin B12 levels in levodopa-treated Parkinsonʼs disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord 2008; 14: 321-325
33 Finsterer J, Iglseder S, Wanschitz J. et al. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand 2019; 139: 92-105
34 Zis P, Sarrigiannis PG, Rao DG. et al. Chronic idiopathic axonal polyneuropathy: a systematic review. J Neurol 2016; 263: 1903-1910
35 Finnerup NB, Attal N. Pharmacotherapy of neuropathic pain: time to rewrite the rulebook?. Pain Manag 2016; 6: 1-3
36 Finnerup NB, Attal N, Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis. Lancet Neurol 2015; 14: 162-173
37 Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 2010; 107: 543-551
38 Haanpaa M, Cruccu G, Nurmikko TJ. et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain 2016; 20: 316-328 10.1002/ejp.731